专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120041079A1 DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS 审中-公开
标题翻译：由疏水性氨基酸功能化的地西泮
公开(公告)号：US20120041079A1
公开(公告)日：2012-02-16
申请号：US13250803
申请日：2011-09-30
申请人： Gerard SOULA , Olivier Soula , Remi Soula , Richard Charvet
发明人： Gerard SOULA , Olivier Soula , Remi Soula , Richard Charvet
IPC分类号： A61K47/36 , C07H15/18 , C07H15/04 , C07H17/02
CPC分类号： A61K31/721 , A61K47/36 , C08B37/0021
摘要： Dextran of the following general formula I: is described, wherein R represents a chain containing from 1 to 15 carbon atoms and having at least one acid functional group prior to attachment to AA, the chain optionally being branched and/or unsaturated and containing one or more heteroatoms, such as O, N or/and S, F represents an ester, a carbamate or an ether, AA represents a hydrophobic amino acid radical, L or D, derived from a coupling between an amine of an amino acid and at least one acid functional group of R; the amino acid, prior to attachment to R, being selected from the group consisting of tryptophan, phenylalanine, leucine, isoleucine, alanine and valine, and alcohol, amide or decarboxylated derivatives thereof, and alkaline cation salts thereof, i represents the molar fraction of substituent F—R-[AA]n per glycosidic unit and is from 0.1 to 2, n represents the molar fraction of R groups substituted by AA and is from 0.05 to 1, and wherein for R groups not substituted by AA, the acid(s) of the group R are alkaline cation carboxylates such as Na or K.
摘要翻译：描述了以下通式I的葡聚糖，其中R表示含有1至15个碳原子并且在与AA连接之前具有至少一个酸官能团的链，该链任选是支链和/或不饱和的，并且含有一个或更多的杂原子，例如O，N或/和S，F代表酯，氨基甲酸酯或醚，AA代表疏水性氨基酸基团，L或D衍生自氨基酸的胺与至少一个酸官能团的R; 氨基酸在与R连接之前选自色氨酸，苯丙氨酸，亮氨酸，异亮氨酸，丙氨酸和缬氨酸，以及其醇，酰胺或其脱羧基衍生物及其碱性阳离子盐，i表示取代基F-R- [AA] n，为0.1〜2，n表示被AA取代的R基的摩尔分数，为0.05〜1，对于不被AA取代的R基，酸（的基团R是碱性阳离子羧酸盐，例如Na或K.

2. 发明申请

US20110301086A1 Complex polymere amphiphile-PDGF 有权
标题翻译：复合多聚体两亲物 - PDGF
公开(公告)号：US20110301086A1
公开(公告)日：2011-12-08
申请号：US13067299
申请日：2011-05-23
申请人： Latifa Dahri-Correia , Jose Correia , Guy Dubreucq , David Duracher , Remi Soula , Olivier Soula , Gerard Soula
发明人： Latifa Dahri-Correia , Jose Correia , Guy Dubreucq , David Duracher , Remi Soula , Olivier Soula , Gerard Soula
IPC分类号： A61K38/18 , A61P17/02 , C07K17/02 , C07K17/10 , C07K17/12
CPC分类号： A61K47/36 , A61K38/1858
摘要： Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups.
摘要翻译：物理和化学稳定的水溶性两亲聚合物-PDGF络合物，其特征在于两亲性聚合物包括用疏水取代基和亲水基团官能化的亲水性聚合物骨架。

3. 发明申请

US20110027363A1 Nouvelle forme d'administration de proteines osteogeniques 审中-公开
标题翻译：新颖的营养成分
公开(公告)号：US20110027363A1
公开(公告)日：2011-02-03
申请号：US12591447
申请日：2009-11-19
申请人： Remi SOULA , Olivier SOULA , Gerard SOULA
发明人： Remi SOULA , Olivier SOULA , Gerard SOULA
IPC分类号： A61K38/18 , A61K38/02 , A61K38/16
CPC分类号： A61K9/143 , A61K9/0019 , A61K9/0024 , A61K9/19 , A61K33/06 , A61K33/42 , A61K38/1841 , A61K38/1858 , A61K38/1875 , A61K45/06 , A61K47/02 , A61L27/227 , A61L27/46 , A61L27/54 , A61L2300/252 , A61L2300/414 , A61L2300/45 , A61K2300/00
摘要： Osteogenic compositions are formed from a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, the coprecipitate being in divided form. A process for preparing the coprecipitate in divided form contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products, kits and medical devices comprising the coprecipitate.
摘要翻译：成骨组合物由共沉淀物形成，共沉淀物含有至少一种不溶性钙盐和至少一种成骨蛋白质，共沉淀物是分开形式的。制备分散形式的共沉淀物的方法包含至少一种不溶性钙盐和至少一种成骨蛋白质和多糖之间的复合物。本发明还涉及包含共沉淀物的制剂，药物产品，试剂盒和医疗装置。

4. 发明申请

US20100305035A1 Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative 有权
公开(公告)号：US20100305035A1
公开(公告)日：2010-12-02
申请号：US12662184
申请日：2010-04-05
申请人： Remi Soula , Olivier Soula , Gerard Soula , Richard Charvet
发明人： Remi Soula , Olivier Soula , Gerard Soula , Richard Charvet
IPC分类号： A61K38/18 , C07H3/06 , A61P19/00
CPC分类号： A61K31/715 , A61K9/19 , A61K31/721 , A61K45/06 , A61K47/36 , C08B37/00 , C08B37/0006 , C08B37/0018 , C08B37/0021 , C08B37/0024 , C08B37/0045 , C08B37/0054 , C08B37/0057 , C08B37/0072 , C08B37/0084 , A61K2300/00
摘要： The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.

5. 发明申请

US20100184965A1 Complex consisted of a polysaccharide and an HBP 有权
标题翻译：复合物由多糖和HBP组成
公开(公告)号：US20100184965A1
公开(公告)日：2010-07-22
申请号：US12585886
申请日：2009-09-28
申请人： Olivier Soula , Remi Soula , Martin Gaudier , Gerard Soula
发明人： Olivier Soula , Remi Soula , Martin Gaudier , Gerard Soula
IPC分类号： A61K47/48 , C08B37/04 , C08B15/06 , C08B37/00
CPC分类号： A61K9/0019 , A61K9/19 , A61K38/1825 , A61K38/185 , A61K38/1866 , A61K38/27 , A61K38/29 , A61K47/42 , A61K47/61
摘要： The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.
摘要翻译：本发明涉及由多糖和HBP组成的复合物，所述多糖由（1,6）和/或（1,4）和/或（1,3）和/或（1,2）的糖苷键组成）类型并用至少一种可成盐或盐化的色氨酸衍生物官能化。本发明还涉及包含根据本发明的复合物和由（1,6）和/或（1,4）和/或（1,3）和/或（1,3）的糖苷键组成的多糖和/ 或（1,2）型，并用至少一种可成盐或盐化的色氨酸衍生物官能化，用于制备稳定HBP的药物制剂。

6. 发明申请

US20100167991A1 Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative 审中-公开
标题翻译：包含被疏水性醇衍生物取代的羧基官能团的多糖
公开(公告)号：US20100167991A1
公开(公告)日：2010-07-01
申请号：US12588149
申请日：2009-10-06
申请人： Remi Soula , Olivier Soula , Gerard Soula , Richard Charvet
发明人： Remi Soula , Olivier Soula , Gerard Soula , Richard Charvet
IPC分类号： A61K38/14 , C07H5/00 , C07H5/10 , A61K38/16 , A61P17/02 , C08B37/04 , A61K47/36
CPC分类号： C08B37/0021 , A61K31/715 , A61K31/721 , A61K47/36 , C08B37/00 , C08B37/0006 , C08B37/0018 , C08B37/0024 , C08B37/0045 , C08B37/0054 , C08B37/0057 , C08B37/0072 , C08B37/0084
摘要： The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.
摘要翻译：本发明涉及包含羧基官能团的多糖，其中至少一个被疏水性醇的衍生物取代。本发明还涉及包含根据本发明的多糖和至少一种活性成分之一的药物组合物。它还涉及药物组合物，其中活性成分选自蛋白质，糖蛋白，肽和非肽治疗分子。本发明还涉及根据本发明的官能化多糖在制备如上所述的药物组合物中的用途。

7. 发明申请

US20080293635A1 Angiogenic composition 审中-公开
标题翻译：血管生成成分
公开(公告)号：US20080293635A1
公开(公告)日：2008-11-27
申请号：US12078443
申请日：2008-03-31
申请人： Olivier Soula , Gerard Soula , Remi Soula , Rosy Eloy
发明人： Olivier Soula , Gerard Soula , Remi Soula , Rosy Eloy
IPC分类号： A61K38/16 , A61P9/00
CPC分类号： A61K9/0014 , A61K38/1858 , A61K47/61
摘要： The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic.In an embodiment, the PDGF is selected from the group of the PDGFs (platelet-derived growth factors) and the amphiphilic polymer is selected from the group: The invention relates also to the therapeutic composition is in the form of a gel, a cream, a solution, a spray, a paste or a patch or a dressing.
摘要翻译：本发明涉及制备用于在其施用部位促进血管发生的治疗组合物的两亲性聚合物，其包含聚合物和PDGF之间的复合物，其中所述聚合物是两亲性的。在一个实施方案中，PDGF选自PDGF（血小板衍生生长因子）组，两亲性聚合物选自：本发明还涉及治疗组合物，其形式为凝胶，霜剂，溶液，喷雾剂，糊剂或贴剂或敷料。

8. 发明申请

US20070265192A1 Telechelic Homopolyamino Acids Functionalized with Hydrophobic Groups, and Their Applications, Especially Therapeutic Applications 失效
标题翻译：用疏水基团功能化的远端肝氨基酸及其应用，特别是治疗应用
公开(公告)号：US20070265192A1
公开(公告)日：2007-11-15
申请号：US10574475
申请日：2004-09-28
申请人： Rémi Soula , You-Ping Chan , Gerard Soula , Olivier Breyne
发明人： Rémi Soula , You-Ping Chan , Gerard Soula , Olivier Breyne
IPC分类号： A61K47/30 , A61K38/28 , A61P3/10 , C07C229/12
CPC分类号： A61K8/88 , A61K9/1075 , A61K9/5146 , A61K47/34 , A61K47/645 , A61Q19/00 , C08G69/10 , C08G73/028 , C08L79/02
摘要： The invention relates to novel materials based on biodegradable homopolyamino acids and which can be used for the vectorization of (an) active ingredient(s) (AI). The invention also relates to novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on said homopolyamino acids. The aim of the invention is to produce a novel polymer raw material which can be used for the vectorization of AI and which meets all specifications in an optimum manner: biocompatibility, biodegradability, the ability to become easily associated with a large number of active ingredients or to solubilize them and to release said ingredients in vivo. According to the present invention, which primarily relates to linear homopolyamino acids having aspartic or glutamic units and whose extremities include hydrophobic groups having 8-30 carbon atoms. Said homopolymers are amphiphilic and anionic and can easily be transformed at low cost into particles for the vectorization of active ingredients. Said particles can form stable aqueous colloidal suspensions.
摘要翻译：本发明涉及基于可生物降解的均聚氨基酸的新型材料，其可用于（a）活性成分（AI）的向量化。本发明还涉及基于所述均聚氨基酸的新型药物，化妆品，饮食或植物检疫组合物。本发明的目的是生产一种新颖的聚合物原料，其可用于AI的载体化并且以最佳方式满足所有规格：生物相容性，生物降解性，与许多活性成分容易相关的能力或以溶解它们并在体内释放所述成分。根据本发明，其主要涉及具有天冬氨酸或谷氨酸单元的线性均聚氨基酸，其末端包括具有8-30个碳原子的疏水基团。所述均聚物是两亲性的和阴离子的，并且可以容易地以低成本转化成用于活性成分载体化的颗粒。所述颗粒可以形成稳定的水性胶体悬浮液。

9. 发明申请

US20070166378A1 Oral ribavirin pharmaceutical compositions 审中-公开
公开(公告)号：US20070166378A1
公开(公告)日：2007-07-19
申请号：US11449675
申请日：2006-06-09
申请人： Florence Guimberteau , Catherine Castan , Remi Meyrueix , Gerard Soula
发明人： Florence Guimberteau , Catherine Castan , Remi Meyrueix , Gerard Soula
IPC分类号： A61K31/7056 , A61K9/22
CPC分类号： A61K9/5026 , A61K9/2077 , A61K9/48 , A61K9/5042 , A61K31/7056
摘要： The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C virus by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of patients. Said composition comprises at least one modified release form of ribavirin, the bio-absorption time BAT of which is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 h and more preferably between 4 and 12 h. Said composition is a reservoir type form or a matrix type form. Said composition is a gastric retentive system or a multiparticulate form.

10. 发明授权

US5535048A Nonlinearly optically active compounds 失效
标题翻译：非线性光学活性化合物
公开(公告)号：US5535048A
公开(公告)日：1996-07-09
申请号：US210995
申请日：1994-03-21
申请人： Gerard Mignani , Gerard Soula , Remi Meyrueix
发明人： Gerard Mignani , Gerard Soula , Remi Meyrueix
IPC分类号： G02F1/35 , C07C211/44 , C07C215/16 , C07C255/37 , C07C255/42 , C07D215/12 , C07D217/04 , C07D221/06 , C07D339/06 , C07D455/04 , C07D471/04 , G02F1/355 , G02F1/361 , C07D451/02
CPC分类号： G02F1/3612 , C07C255/37 , C07C255/42 , C07D455/04 , G02F1/3611 , G02F1/3614 , C07C2101/16
摘要： Novel nonlinearly optically active compound's, well suited for electrooptical applications, have the following general formulae: ##STR1## wherein D is an electron donor group; A and A.sub.1, which may be identical or different, are each an electron acceptor group; and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a lower alkyl radical or a hydrogen atom.
摘要翻译：新的非线性光学活性化合物，非常适合于电光学应用，具有以下通式：（I）和oup; A和A1可以相同或不同，各自为电子受体基团; 并且R 1，R 2，R 3和R 4各自为低级烷基或氢原子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式